- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01861080
Korean Registry of Target Organ Damages in Hypertension (KorHR)
Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Background: the exact prevalence of target organ damages in Korean hypertensives are unknown.
Study Objective: to investigate the prevalence of target organ damages in Korean patients with incident hypertension.
Study Design: prospective, multi-center and observational study
Study Populaton: approximately 5000 consecutive patients with incident hypertension, who visited outpatients clinics and agreed to participate in the registry
Primary outcome
Subclinical organ damages
- left ventricular hypertrophy on electrocardiogram or echocardiography
- increased intima media thickness of carotid artery (> 0.9 mm) or plaque
- increased pulse wave velocity (> 12 m/s)
- low estimated glomerular filtration rate (< 60 ml/min/1.73 m2) or creatinine clearance (<60 ml/min)
Established CV or renal disease
- cerebrovascular disease: ischemic stroke; cerebral stroke; transient ischemic attack
- Heart disease: myocardial infarction; angina; coronary revascularization; heart failure
- Renal disease: diabetic retinopathy; serum creatinine M > 133, W > 124 mmol/L; proteinuria > 300 mg/24 hr
- Peripheral artery disease
- Advanced retinopathy: hemorrhage or exudates, papilledema
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
Gyeonggido
-
Hwaseong, Gyeonggido, Korea, Republikken, 445-170
- Hallym University Dongtan Sacred Heart Hospital,
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- age≧30years
- primary incident hypertension
- singed informed consent
Exclusion Criteria:
- participated in other clinical trials
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
incident hypertensives
Inclusion Criteria:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
left ventricular hypertrophy
Tidsramme: at enrollment
|
left ventricular hypertrophy on electrocardiogram or echocardiography Sokolow-Lyon > 38 mm; left ventricular mass index male >= 125 g/m2, female >=110 g/m2)
|
at enrollment
|
Intima media thickness of carotid artery
Tidsramme: at enrollment
|
increased intima media thickness of carotid artery (> 0.9 mm) or presence of plaque
|
at enrollment
|
pulse wave velocity
Tidsramme: at enrollment
|
increased pulse wave velocity (> 12 m/s)
|
at enrollment
|
kidney function
Tidsramme: at enrollment
|
low estimated glomerular filtration rate (< 60 ml/min/1.73
m2) or creatinine clearance (< 60 ml/min)
|
at enrollment
|
cerebrovascular accident
Tidsramme: at enrollment
|
ischemic stroke, cerebral hemorrhage, or transient ischemic attack confirmed by a neurologist
|
at enrollment
|
renal disease
Tidsramme: at enrollment
|
serum creatinine male > 1.5 mg/dl, female > 1.4 mg/dl; proteinuria > 300 mg/24hr
|
at enrollment
|
peripheral artery disease
Tidsramme: at enrollment
|
ankle to brachial blood pressure ratio < 0.9
|
at enrollment
|
retinopathy
Tidsramme: at enrollment
|
retinal hemorrhage or exudate, papilledema confirmed by an ophthalmologist
|
at enrollment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Hypertension
Tidsramme: at enrollment
|
high blood pressure confirmed by ambulatory blood pressure monitoring (24hr average systolic blood pressure >=135 mm Hg, diastolic blood pressure >= 85 mm Hg
|
at enrollment
|
Dyslipidemia
Tidsramme: at enrollment
|
total cholesterol 190 mg/dl or LDL > 115 mg/dl, HDL male < 40 mg/dl, female < 46 mg/dl or triglyceride > 150 mg/dl
|
at enrollment
|
abnormal fasting plasma glucose
Tidsramme: at enrollment
|
abnormal fasting plasma glucose (102-125 mg/dl)
|
at enrollment
|
abdominal obesity
Tidsramme: at enrollment
|
waist circumference male > 102 cm, female > 88 cm
|
at enrollment
|
diabetes mellitus
Tidsramme: at enrollment
|
fasting plasma glucose >= 126 mg/dl; postload plasma glucose > 198 mg/dl
|
at enrollment
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
major cardiovascular events
Tidsramme: after follow-up period of 36 months
|
death, stroke, myocardial infarction and heart failure(confirmed by a cardiologist)
|
after follow-up period of 36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Kyu-Hyung Ryu, MD, PhD, Dongtan Sacred Heart Hospital, Hallym University
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2012-005
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hypertensjon
-
University Hospital of CologneUkjentNAFLD; Hypertensjon, White-Coat Hypertension, Masked HypertensionTyskland
-
Karolinska InstitutetFullførtWhite Coat Hypertension
-
Clinical Hospital Centre ZagrebEuropean Society of HypertensionUkjentWhite Coat Hypertension | Blodtrykk | LivsstilsrisikoreduksjonIsrael, Hellas, Belgia, Tyskland, Armenia, Østerrike, Bulgaria, Kroatia, Tsjekkia, Estland, Italia, Libanon, Litauen, Nederland, Polen, Portugal, Romania, Serbia, Spania, Sverige, Ukraina, Storbritannia
-
Regional Hospital HolstebroFullførtSunn | White Coat Hypertension | Essensiell hypertensjonDanmark
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Aktiv, ikke rekrutterendeWhite Coat Hypertension | Hypertensjon, viktigForente stater
-
University of Alabama at BirminghamTroy UniversityFullførtHypertensjon | Hypertensjon, motstandsdyktig mot konvensjonell terapi | Ukontrollert hypertensjon | Hypertensjon, hvit pelsForente stater
-
PD Dr. Grégoire WuerznerSwiss National Science FoundationFullførtHypertensjon | Overvekt | White Coat Hypertension | Resistent hypertensjonSveits
-
University Hospital, ToursFullførtPTFE-dekkede stenter versus nakne stenter i TIPS (Transjugulær Intra-hepatisk Porto-systemisk shunt)Cirrhotic Portal HypertensionFrankrike
-
Sun Yat-sen UniversityFullførtHepatocellulært karsinom (HCC) | Cirrhotic Portal HypertensionKina